View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 29, 2021

Link Health to obtain global rights for Bone Therapeutics’ cell therapy

The new agreement is in addition to the deal entered last year to develop and market ALLOB.

Link Health Pharma has entered a non-binding term sheet to acquire worldwide rights for Bone Therapeutics’ allogeneic bone cell therapy, ALLOB.

ALLOB contains human bone-forming cells obtained from adult donors’ cultured bone marrow mesenchymal stem cells.

The latest collaboration comes after the two companies and Shenzhen Pregene Biopharma Company signed an exclusive licence agreement in October last year for developing, producing and marketing ALLOB in Hong Kong, Macau, Singapore, Taiwan, Thailand and South Korea.

Under this previous deal, Pregene obtained rights for cell therapy in China.

All three companies will jointly develop ALLOB.

According to the latest agreement, Link Health will handle all future development, which includes the ongoing ALLOB TF2 Phase IIb trial, as well as costs, scale-up and production of ALLOB.

As no upfront payment is anticipated, the agreement will not have an immediate direct monetary effect other than to fund all costs linked to the development of the allogeneic bone cell therapy.

However, Bone Therapeutics will be eligible for up to a total of $67.83m (€60m) as commercial milestone payments and tiered royalty payments up to 25% on net product sales.

Bone Therapeutics will leverage its broad cell therapy capabilities to develop cell and gene therapy products that possess anti-inflammatory and immunomodulatory properties to treat acute life-threatening ailments.

Bone Therapeutics CEO Miguel Forte said: “The existing collaboration between Bone Therapeutics, Link Health and Pregene for the development of ALLOB in Asia has progressed swiftly and fully in line with the anticipated schedule.

“Bone Therapeutics expanding its collaboration with Link Health will allow for the development and potential availability of ALLOB globally for the benefit of patients with high orthopaedic unmet medical needs.”

Presently, ALLOB is being analysed in a double-blind, randomised, placebo-controlled Phase IIb clinical trial in individuals with an increased risk of tibial fractures.

The trial will investigate if ALLOB along with the standard of care stabilisation surgical procedure can speed up fracture healing after a follow-up of three months and avert late-stage complications, versus placebo.

The final agreement is anticipated to conclude by this year-end subject to meeting necessary conditions.

In April, Guangzhou Link Health Pharma entered a term sheet for a strategic agreement with George Clinical to unveil a clinical development company to deliver trials.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology